The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on ...

Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization ...

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

BeOne Medicines (NASDAQ:ONC) gains FDA approval for a new tablet version of Brukinsa, simplifying dosage for patients.

A research team at the University of Barcelona shows how allopurinol may prevent aortic aneurysm in Marfan syndrome, paving the way for new clinical trials.

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...